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Targeting hedgehog signaling reduces self-renewal in
embryonal rhabdomyosarcoma
S Satheesha1,4, G Manzella1,4, A Bovay1, EA Casanova1, PK Bode1,2, R Belle1, S Feuchtgruber3, P Jaaks1, N Dogan1, E Koscielniak3
and BW Schäfer1
Current treatment regimens for rhabdomyosarcoma (RMS), the most common pediatric soft tissue cancer, rely on conventional
chemotherapy, and although they show clinical beneﬁt, there is a signiﬁcant risk of adverse side effects and secondary tumors later
in life. Therefore, identifying and targeting sub-populations with higher tumorigenic potential and self-renewing capacity would
offer improved patient management strategies. Hedgehog signaling has been linked to the development of embryonal RMS (ERMS)
through mouse genetics and rare human syndromes. However, activating mutations in this pathway in sporadic RMS are rare and
therefore the contribution of hedgehog signaling to oncogenesis remains unclear. Here, we show by genetic loss- and gain-of-
function experiments and the use of clinically relevant small molecule modulators that hedgehog signaling is important for
controlling self-renewal of a subpopulation of RMS cells in vitro and tumor initiation in vivo. In addition, hedgehog activity altered
chemoresistance, motility and differentiation status. The core stem cell gene NANOG was determined to be important for ERMS
self-renewal, possibly acting downstream of hedgehog signaling. Crucially, evaluating the presence of a subpopulation of tumor-
propagating cells in patient biopsies identiﬁed by GLI1 and NANOG expression had prognostic signiﬁcance. Hence, this work
identiﬁes novel functional aspects of hedgehog signaling in ERMS, redeﬁnes the rationale for its targeting as means to control ERMS
self-renewal and underscores the importance of studying functional tumor heterogeneity in pediatric cancers.
Oncogene advance online publication, 20 July 2015; doi:10.1038/onc.2015.267
INTRODUCTION
Rhabdomyosarcoma (RMS) comprises of a heterogeneous set of
neoplasms that possess features of halted skeletal muscle
differentiation and is the most common pediatric soft tissue
cancer. The two major histological subtypes, embryonal (ERMS)
and alveolar, differ in their molecular cytogenetic proﬁles, clinical
presentations and prognosis. ERMS accounts for about 70% of
RMS cases and possesses a relatively more complex genomic
landscape with frequent alterations within the RAS pathway.1–3
Currently, pre-treatment histology and initial clinical presentation
guide risk stratiﬁcation to determine therapy intensity. Although a
majority of ERMS patients have good prognosis, clinical beneﬁt
from current treatments has reached a plateau and prognosis is
dismal for high-risk metastatic ERMS patients.2 Therefore, there is
an urgent need to implement rationally selected targeted
treatment options to reduce rate of relapse, therapy burden and
improve clinical outcome.
Hedgehog pathway, a master developmental signaling system,
is commonly activated in sporadic ERMS.4–7 Canonical hedgehog
pathway is a ligand-activated signaling system with three ligand
variants—Sonic (SHH), Indian (IHH) and Desert hedgehog (DHH).
The secreted ligands bind to the extracellular domain of the
Patched (PTCH) receptor leading to the release of the receptor
Smoothened (SMO). SMO then translocates to the primary cilium
to activate the downstream signaling cascade that involves
relieving inhibition of Suppressor of Fused (SUFU) on activity of
the GLI transcription factors. The ligands available for activation
can be titrated by the transmembrane Hedgehog-interacting
protein (HHIP). There are three GLI transcription factors, of which
GLI1 is the most potent transactivator. Low-level gains in the GLI1
genomic region have been noted in ERMS patients.5 The
expression of GLI target genes, which include components of
the hedgehog pathway such as GLI1, PTCH1 and HHIP, can be
used to study pathway activation status.8,9
Recent data suggest that ERMS is a hierarchically organized
tumor.10–12 At present, little is known about the pathways used to
maintain self-renewal and tumorigenic properties of ERMS tumor-
propagating cells (TPCs). In the present study, using small molecules
and various genetic approaches, we show that hedgehog signaling
modulates ERMS TPC features of self-renewal and tumor initiation.
We describe additional novel roles played by this pathway in
determining ERMS chemoresistance, invasion and differentiation,
and identify NANOG as a functionally important self-renewal gene
that could be downstream of the pathway, previously unknown in
any soft tissue sarcoma. Importantly, we show that functional intra-
tumoral heterogeneity identiﬁed by the presence of hedgehog-
active TPC markers in ERMS patients is clinically relevant.
RESULTS
Hedgehog signaling is necessary for ERMS self-renewal and
efﬁcient tumorigenesis
We analyzed the expression of hedgehog pathway components in
ERMS sphere cultures that are enriched in de-differentiated, self-
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renewing and highly tumorigenic cells.11 Quantitative PCR (qPCR)
analysis revealed that the expression of hedgehog target genes
was upregulated in ERMS spheres (Figure 1a and Supplementary
Figures 1a and c) and xenografts from ERMS cell lines and patient-
derived tumors (Figure 1b and Supplementary Figures 1d and f)
compared with adherent cultures. The addition of hedgehog
agonist SAG1.3 during primary sphere formation led to enhanced
secondary sphere formation (RD: +50% and RH36: +170%;
Figure 1c) indicating that activating the hedgehog pathway could
increase self-renewal in ERMS cells. Similarly, the use of two
independent siRNAs against SUFU led to signiﬁcantly increased
sphere-initiating ability (Figure 1d and Supplementary Figures 1g
and i). To exclude any extraneous effects of sphere media
components on hedgehog pathway activation, ERMS adherent
cells were treated with SAG1.3 prior to plating in sphere media.
Again, treatment led to a dose-dependent increase in sphere
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initiation without affecting cell cycle proﬁle or viability (Figure 1e
and Supplementary Figures 1j and l).
We performed single cell cloning of RD cell line that showed
heterogeneous expression of GLI1 to isolate subpopulations with
varying levels of hedgehog pathway activity. All the 29 clones
analyzed also showed heterogeneous GLI1 expression (data not
shown), indicating that the pathway is dynamically controlled. We
performed sphere-initiation studies using two clones (Clones E8
and H3) that had fewer GLI1high cells than bulk RD cells and Clone
F2 that was enriched in GLI1high cells (Supplementary Figures 2a
and b). Clone E8 and Clone H3 had signiﬁcantly lower
spherogenicity (by 50% and 40%, respectively) and Clone F2
had increased sphere-initiating capacity (+30%; Supplementary
Figure 2c) highlighting that a population-intrinsic level of hedge-
hog signaling could determine self-renewal capacity.
To study the role of hedgehog pathway activation in more
detail, we generated stable cell lines that overexpressed full-
length GLI1 (pCMV-GLI1). At the endogenous level, we could
detect the more stable shorter isoform of GLI1 (~130 kDa;
Figure 1f) reportedly derived from the 160kDa full-length
protein.13 pCMV-GLI1 cells showed an increased expression of
downstream targets, PTCH1 and HHIP, compared with the control
(Figure 1f and Supplementary Figures 2d and e). We also found
the expression of PGDFRA, a known hedgehog target gene that
was previously implicated in ERMS biology,14,15 to be increased
(Supplementary Figures 2d and e). pCMV-GLI1 cells possessed
enhanced primary sphere-forming and colony-forming abilities
(Figures 1g and h and Supplementary Figure 2f). When plated for
secondary sphere formation, the relative increase in sphere-
initiation capacity became more apparent (RD: +87% and RH36:
+230%) indicating improved self-renewal. Importantly, pCMV-GLI1
cells displayed signiﬁcantly faster tumor growth rate when
injected orthotopically in NOD/SCID mice (Figures 1i and j). The
xenografts retained GLI1 overexpression (Supplementary Figure
2g) and were conﬁrmed to be of ERMS histotype (Supplementary
Figure 3). Taken together, the active hedgehog pathway in ERMS
cells leads to higher self-renewal and increased tumor-initiating
capacity.
Next, we inhibited the hedgehog pathway both pharmacolo-
gically and genetically. ERMS cells treated with SMO inhibitor
GDC-0449 or GLI inhibitor GANT61 during primary sphere
formation showed decreased sphere numbers (Figure 2a and
Supplementary Figure 4a). GDC-0449 treatment led to an 88%
decrease in secondary sphere formation for RD cells and RH36
cells showed no spheres formation. GANT61 treatment was more
potent because no viable cells were available for secondary
sphere formation from either cell line. Using two independent
siRNAs against GLI1 in adherent cells signiﬁcantly decreased
sphere initiation (Figure 2b and Supplementary Figures 4b and c).
Next, cells were treated with inhibitors (also including the SMO
inhibitor LDE-225) under adherent conditions and then plated for
sphere formation. Dose-dependent decrease in sphere initiation
was observed with all drugs (Figure 2c and Supplementary Figure 4d).
Treatments did not alter cell cycle proﬁle or viability status of the
cells (Supplementary Figures 4e and h). Pre-treatment of RD cells
with GANT61 in vitro led to slower tumor initiation in vivo owing to
reduced hedgehog pathway activity at the time of engraftment
(Figures 2d and e and Supplementary Figures 4i–k).
To study the long-term effects of inhibition, we generated
stable cell lines that overexpressed SUFU (pCMV-SUFU) to inhibit
GLI activity directly or expressed shRNA against SMO (shSMO) to
inhibit the canonical ligand-based hedgehog signaling. Both
inhibitory systems led to decreased target gene expression
(Figures 2f and g and Supplementary Figures 5a and e). Adherent
colony-forming ability, sphere initiation and renewal were
markedly decreased by either hedgehog-inhibition strategies
(Figures 2h and i and Supplementary Figures 5f and g). Although
no signiﬁcant changes occurred in proliferation or cell cycle
proﬁles (Supplementary Figures 5h and n and data not shown),
signiﬁcant decrease in tumor growth kinetics was observed in vivo
(Figures 2j–m). Impressively, RD cells showed no palpable tumor
growth in the majority of hedgehog-inhibited xenografts at the
time when the controls reached maximum allowed tumor
volumes. While tumor initiation rate was 100% for control cells,
only three out of ﬁve mice and three out of seven mice injected
with pCMV-SUFU and shSMO cells, respectively, eventually
developed tumors. Taken together, the inhibition of hedgehog
pathway reduces in vitro self-renewal and in vivo tumor initiation.
Pathway activation seemed to be largely ligand-based because
inhibition of either receptor-mediated or GLI-based hedgehog
signaling led to similar and comparable effects on self-renewal
and tumorigenesis. Accordingly, we found increased expression of
hedgehog ligands DHH and IHH in RH36 spheres and xenografts
(Supplementary Figures 6a and c), and of DHH in RD cells
(Supplementary Figures 6b and d) compared with adherent
cultures. Also, patient-derived xenograft (PDX) samples showed
higher expression of both (RH70) or IHH ligand (RH73) in vivo
(Supplementary Figures 6e and f). DHH and IHH were also found
to be the most commonly expressed hedgehog ligands in ERMS
patient tumors, with on average a higher expression of DHH
(Supplementary Figures 6g and h). Surprisingly, SHH was
expressed only in a minority of tumor biospies and not at all in
adherent cell lines, sphere cultures, xenografts or murine skeletal
muscle. Additionally, using species-speciﬁc qPCR probes, we could
determine that ligand-based signaling was occurring in an
autocrine manner with a minor inverse-paracrine contribution
from the stroma within xenografts (Supplementary Figures 6k and
n). Therefore, ligand-based hedgehog signaling is active in ERMS
and seems to increase under conditions of self-renewal and in vivo
tumorigenesis and, importantly, is necessary for TPC functionality.
Hedgehog signaling alters chemoresistance, differentiation status
and cell motility of ERMS cells
TPCs might also be responsible for tumor recurrence by being
more resistant to chemotherapeutic treatments.16 To test this
notion, we treated our stable cells with serial dilutions of
Figure 1. Activation of hedgehog signaling increases self-renewal and tumorigenicity of ERMS cells. (a) Left panel: Expression levels of
hedgehog signaling components in RD spheres (n= 6; N= 2) compared with adherent monolayer cultures (n= 9; N= 3) by quantitative PCR
(Log10 scale). Right panel: Western Blot anaysis showing expression of indicated proteins in RD adherent and sphere cells. (b) GLI1 RNA
expression levels (relative to HMBS) in patient-derived samples when grown as xenografts (‘in vivo’; n= 6, N= 2) or dissociated and cultured as
adherent cells (‘in vitro’; n= 6, N= 2) determined by qPCR. (c) Sphere-initiation capacity of ERMS cells treated with hedgehog agonist SAG1.3
(500 nM) every 48 h (three rounds) during primary sphere formation and thereafter plated for secondary sphere formation in normal sphere
media (n= 9; N= 3). (d) Sphere formation after siRNA-mediated knockdown of SUFU (10 nM) in RD adherent cells compared with scrambled
control siRNA (N= 2). (e) Sphere formation following 48 h treatment of ERMS adherent cultures with SAG1.3 (n= 5; N= 5). (f) Western blot
analysis of indicated proteins in ERMS stable cell lines. Primary (1°) and secondary (2°) sphere formation measured in ERMS stable lines (g: RD;
N= 3 and h: RH36; N= 3). (i) Tumor growth rate of RD-based stable lines pCMV-Empty (n= 6/6) and pCMV-GLI1 (n= 5/5) injected orthotopically
in NOD/SCID mice. (j) Tumor growth rate of RH36-based stable lines pCMV-Empty (n= 2/6) and pCMV-GLI1 (n= 4/6) injected orthotopically in
NOD/SCID mice. Error bars in i and j represent s.e.m. Each data point in the scatter plots represents a technical replicate with the line drawn at
the mean. In bar graphs, data represent mean± s.d. *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001. FL, full-length.
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irinotecan or doxorubicin that are currently used in clinical
management. We observed on average higher IC50 values for
pCMV-GLI1 cells compared with a control indicating that cells with
increased hedgehog activity are more resistant (Table 1). Con-
versely, cells with inhibited pathway were more sensitive to
conventional drugs. Interestingly, treatment of wild-type RD cells
with increasing doses of irinotecan also enhanced sphere-
initiating capacity, which could be rescued by combined
treatment with hedgehog inhibitor LDE-225 (Supplementary
Figures 7a and b). This implies that high-dose chemotherapy
Figure 2. Inhibition of hedgehog signaling decreases self-renewal and tumorigenicity of ERMS cells. (a) Sphere-initiation capacity of RD cells
treated with small-molecule inhibitors GDC-0449 or GANT61 every 48 h (three rounds) during primary sphere formation and further plated for
secondary sphere formation in normal sphere media (n= 9; N= 3). § No viable cells were recovered for secondary sphere formation. (b) Sphere
formation measured following siRNA (10 nM) mediated GLI1 knockdown in RD adherent cells (n= 6; N= 2). (c) Sphere-formation ability of RD
adherent cells after 48 h treatment with hedgehog inhibitors (n= 12, N= 6 for GDC-0449 and GANT61; n= 6, N= 2 for LDE-225). Tumor growth
rate (d) and tumor weight (e) of RD cells pre-treated in vitro with GANT61 (3μM) (n= 5 per condition). Western blot analysis of indicated
proteins in stable ERMS lines overexpressing tagged SUFU (f; Myc-DDK) and knockdown of SMO (g). Primary (1°) and secondary (2°) sphere
formation measured in ERMS stable lines (h: N= 2 per cell line; i: N= 2-4 per cell line except 2° sphere formation). Tumor growth kinetics of
hedgehog inhibited pCMV-SUFU (j: RD; n= 3/5 and k: RH36; n= 3/6) and control pCMV-Empty (j: RD, n= 5/5 and k: RH36, n= 2/6) cells in NOD/
SCID mice. Tumor growth kinetics of hedgehog inhibited shSMO (l: RD, n= 3/7 and m: RH36, n= 6/7) and control pLKO.1 (l: RD, n= 7/7 and
m: RH36, n= 7/7) cells in NOD/SCID mice. Error bars in d, e, j–m represent s.e.m. In bar graphs, data represent mean± s.d. *Po0.05; **Po0.01;
***Po0.001.
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treatment currently used in clinical management could enrich for
hedgehog-active TPCs.
Next, we evaluated the effect of hedgehog signaling on ERMS
differentiation. Expression of PAX7 is highest in muscle stem cells,
while committed muscle progenitor cells express MYOGENIN.
Therefore, expression of these proteins provides a convenient
readout to assess the differentiation status. Indeed, the expression
of these markers was mutually exclusive also in ERMS cells
indicating that the differentiation programs present during normal
myogenesis are also active in the pathological state (Figure 3a
and Supplementary Figure 7c). pCMV-GLI1 cells possessed
increased PAX7+ cells and concomitantly fewer MYOGENIN+ cells
(Figures 3a–c and Supplementary Figure 7c), whereas inhibition of
the pathway induced differentiation as evidenced by a reduction
in the percentage of PAX7+ and gain in MYOGENIN+ cells
(Figures 3a,b and d,e and Supplementary Figures 7d and e).
Treatment with small molecule modulators induced similar
alterations in the differentiation status (Supplementary Figures
7f and i). Furthermore, signiﬁcant increase in the expression of
terminal muscle differentiation markers CKM and MYL1 was noted
upon long-term treatment with GANT61 (Supplementary
Figure 7j). These data suggest that activation of hedgehog
signaling confers a more stem-like state, whereas pathway
inhibition induces differentiation. We could not ﬁnd signiﬁcant
co-localization of PAX7 and GLI1 expression (data not shown)
indicating that PAX7 may not be a direct target of GLI1. Rather,
hedgehog pathway activation might induce de-differentiation by
reducing the transcriptional activity of pro-differentiation muscle
regulatory factors.17
A previous study evaluating in vivo tumor heterogeneity in a
zebraﬁsh model of ERMS reported that the Myogenin-expressing
(differentiated) compartment had higher invasiveness.12 Concor-
dantly, we observed that the hedgehog-inhibited cells possessed
increased ECM invasion capacity (Figures 3f and g and
Supplementary Figure 8a). This effect was cell autonomous
because coating the membrane ﬁlter with gelatin did not alter
the results (Supplementary Figure 8a). Surprisingly, in the absence
of a basement membrane matrix, the differentiated cells had
much lower migratory ability (Figures 3h and i and Supplementary
Figure 8b), indicating that matrix adhesion probably has an
important role in determining cell motility in ERMS.
NANOG is functionally important for ERMS self-renewal
To identify genes that could be regulated by the hedgehog
pathway in ERMS cells, we used a stem cell-focused qPCR-based
screening approach interrogating 162 genes associated with
developmental pathways and the stem cell phenotype. We found
147 genes to be reliably expressed (Ct valueo35), of which 142
were common to both cell lines. Non-supervised hierarchical
clustering identiﬁed genes either positively or negatively modu-
lated by hedgehog signaling (Figure 3j). In general, we found
more genes to be negatively regulated by the hedgehog signaling
and among them were several components of TGF-β, Wnt and
Notch (in RD cells; data not shown) signaling pathways.
Interestingly, expression of the stem cell transcription factor
NANOG was positively regulated by the hedgehog pathway in
both ERMS cell lines studied. NANOG is a homeodomain-
containing transcription factor essential for establishing
pluripotency18 with a known function in TPC maintenance in
many adult cancers.19 It has already been characterized as a GLI
target gene in neural stem cells, medulloblastoma and glioblas-
toma neurospheres.20,21 Therefore, we chose to further study its
role in ERMS.
First, we conﬁrmed alterations in NANOG expression noted in
the screen on additional samples (Supplementary Figures 9a and
d). Next, ERMS cells were co-immunostained for GLI1 and NANOG.
The expression of both proteins was found to be heterogeneous
and strictly co-localized in both cell lines and primary cells from
three PDX samples (Figure 4a and Supplementary Figures 9e and
f). Upon GLI1 overexpression or SAG1.3 treatment, the percentage
of NANOG-expressing cells increased signiﬁcantly (Figures 4b and
c and Supplementary Figures 10a and c). NANOG expression was
higher in sphere cultures and xenografts than adherent cultures
(Supplementary Figures 10d and g). These data indicate that
NANOG expression correlates with hedgehog pathway activity,
both in ERMS cells and patient samples, implying that it could be a
target gene of the pathway in ERMS similar to observations in
other cancers.
We also reduced NANOG expression in RD cells using transient
and stable genetic means and both approaches led to decreased
sphere formation (Figures 4d and e). Transient overexpression of
NANOG signiﬁcantly improved spherogenicity (Figures 4f and g).
Importantly, ectopic NANOG expression in hedgehog-inhibited
cells rescued the lowered self-renewal ability back to the level of
controls, indicating that NANOG could act epistatic to hedgehog
pathway (Figures 4f and g). We also noted that alteration in
NANOG expression led to a concordant change in the expression
of GLI1 (Supplementary Figures 11a and c), which could be either
due to the effect on overall proportion of ERMS stem cell-like
population marked by GLI1 expression or the direct modulation of
GLI1 expression as previously reported in brain cancers.21
Interestingly the expression of PDGFRA was also decreased upon
NANOG knockdown (Supplementary Figure 11a). To evaluate the
Table 1. Hedgehog pathway modulation alters chemoresistance of ERMS cells
Cell lines Mean absolute IC50 at 72 h (nM± s.d.) Phenotype
Parental Transgenic Irinotecan
(SN-38)a
Relative change in
IC50
c,d
Doxorubicinb Relative change in
IC50
c,d
Hedgehog pathway
activity
Relative
resistance
RH36 pCMV-Empty 11± 6 157± 84 Control
pCMV-GLI1 19± 15 ↑ 73% (ns) 284± 205 ↑ 81% (ns) Increased Increased
RD pCMV-Empty 54± 30 186± 124 Control
pCMV-GLI1 94± 55 ↑ 74% (*) 286± 249 ↑ 54% (ns) Increased Increased
pCMV-SUFU 37± 15 ↓ 31% (ns) 139± 135 ↓ 25% (ns) Decreased Decreased
RH36 pLKO.1 23± 15 221± 130 Control
shSMO 10± 5 ↓ 56% (**) 105± 28 ↓ 52% (*) Decreased Decreased
RD pLKO.1 78± 36 198± 135 Control
shSMO 39± 16 ↓ 50% (***) 177± 121 ↓ 10% (ns) Decreased Decreased
Abbreviations: ERMS, embryonal rhabdomyosarcoma. aN= 5 for RD-based cell lines; N= 4 for RH36-based cell lines. bN= 4 for all cell lines . c‘↑’ – IC50 increased
by; ‘↓’ – IC50 decreased by.
dIn parenthesis are presented the statistical signiﬁcance of the relative difference in the IC50 values: ns-not signiﬁcant; *Po0.05;
**Po0.01.
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Figure 4. Nanog is a functionally important target gene of hedgehog pathway in ERMS. (a) Representative images of RD cells co-stained for
GLI1 and NANOG expression. All images were taken at × 400 magniﬁcation. Scale bar represents 20 μm. Quantiﬁcation, using ImageJ, of
NANOG-expressing cellular compartments normalized to DAPI-stained nuclei per viewing ﬁeld in ERMS stable lines (b; N= 2) and RD cells
treated with SAG1.3 (500 nM) for 48 h (c; N= 2). (d) Sphere formation in RD cells with stable knockdown of NANOG (shNANOG; N= 3).
(e) Sphere formation measured following siRNA (10 nM) mediated NANOG knockdown in RD adherent cells (N= 2). (f and g) Primary sphere
formation upon transient overexpression of NANOG in RD cells (n= 12; N= 2). Data represent mean± s.d. Secondary sphere formation in RD
(h) and RH36 (i) rescue systems (N= 3). (j) Tumor growth rate of RH36 cells in NOD/SCID mice (n= 6/6 per cell line). Error bars represent s.e.m.
*Po0.05, **Po0.01, ***Po0.001. ns, not signiﬁcant.
Figure 3. Hedgehog signaling alters the differentiation status and motility of ERMS cells. (a) Representative images of RD cells stained for PAX7
and MYOGENIN expression. All images were taken at × 400 magniﬁcation. Scale bar represents 20 μm. (b and d) Quantiﬁcation of percentage
of PAX7- or MYOGENIN-positive RD cells normalized to DAPI-stained nuclei counted per viewing ﬁeld, using ImageJ (n= 4). (c and e)
Quantiﬁcation of PAX7- or MYOGENIN-positive RH36 cells (n= 5). (f and g) Total number of RD cells that could invade through matrigel-coated
porous membrane ﬁlter towards a growth serum gradient over 48 h (n= 3; N= 3). (h and i) Relative migration of RD cells across porous
membrane ﬁlter towards a growth serum gradient over 48 h (n= 15; N= 3). (j) Non-supervised hierarchical clustering of genes positively and
negatively regulated by the hedgehog pathway common to both RD and RH36 cell lines. Each column represents the average RNA expression
fold change for the labelled genes within the hedgehog-modulated stable cell line made relative to its respective empty vector control (n= 2;
N= 2). *Po0.05, **Po0.01, ***Po0.001. Data represent mean± s.d.
Hedgehog-driven ERMS tumor-propagating cells
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role of NANOG on self-renewal and tumor growth independently,
we generated stable rescue lines where NANOG expression was
decreased in GLI1 overexpressing cells (GLI1+shNANOG) and
corresponding empty vector (pCMV+pLKO.1) or GLI1 overexpres-
sion only controls (GLI1+pLKO.1) (Supplementary Figures 11d and
e). When both RD and RH36 rescue systems were allowed to form
spheres, secondary sphere formation was increased signiﬁcantly in
the GLI1+pLKO.1 cells for both cell lines (RD: +108% and RH36:
+59%) and impressively, NANOG knockdown rescued it back to
almost control levels (Figures 4h and i). Additionally, the in vivo
tumor growth rate of GLI1+shNANOG cells was signiﬁcantly lower
than control cells (Figure 4j and Supplementary Figures 11f and g).
Taken together, NANOG emerges as a functionally important gene
for TPC properties in ERMS that could act downstream of the
hedgehog signaling.
GLI1 and NANOG expression has prognostic value for ERMS
patients
Finally, we evaluated whether the expression of GLI1 and NANOG
is clinically relevant. To this end, we performed a double-blind
analysis of GLI1 and NANOG expression in a previously described
set of tissue microarrays (TMA) with multiple tumor cores from 116
ERMS patient samples using immunohistochemistry.22 Reliable
protein expression status was obtained for 91 patients, most of
whom were negative for both proteins. However, patients positive
for one were in 80% of the cases also positive for the other. We
observed that only tumor cells expressed GLI1 and NANOG and,
importantly, the expression was heterogeneous as seen in cell
cultures (Figure 5a and Supplementary Figure 11h). Correlation
with clinical data revealed that the expression of GLI1 alone could
predict signiﬁcantly worse overall survival and a similar trend was
observed for NANOG status (Figures 5b and c). These patients also
tended to have worse event-free survival although the data did
not reach statistical signiﬁcance (Supplementary Figures 11i and j).
Importantly, it was only when the patients were distinguished
based on the presence of GLI1+ and NANOG+ cellular sub-
populations within their tumors that we observed statistically
signiﬁcant worse event-free and overall survival (Figures 5d and e).
The distribution of patient- and tumor-related parameters was
similar among patient subgroups. Chi-square tests revealed no
signiﬁcant differences between the groups (data not shown).
Figure 5. Presence of GLI1+ and NANOG+ compartment predicts adverse patient survival. (a) Representative images of immunohistochemical
staining for GLI1 and NANOG within an ERMS patient tumor core. All images were taken at × 400 magniﬁcation. Scale bar represents 20 μm.
Kaplan–Meier curve representing overall survival of 91 ERMS patients either negative (black line) or positive (grey line) for GLI1 (b) or NANOG
(c) alone. Kaplan–Meier curve representing event-free survival (d) and overall survival (e) of 91 ERMS patients determined to be negative
(black line) for GLI1 and/or NANOG (‘GLI1- & or / NANOG-’) or positive (grey line) for both GLI1 and NANOG expression (‘GLI1+ & NANOG+’). The
P-values were generated using log-rank test.
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Owing to low patient numbers, it was not possible to assess
whether GLI1 and/or NANOG expression could be used as
independent prognostic markers. Nevertheless, our analysis
reveals that intra-tumoral heterogeneity represented by the
expression of both GLI1 and NANOG can help identify a subset
of ERMS patients with worse outcome and therefore is clinically
relevant.
DISCUSSION
Although previous studies have identiﬁed hedgehog signaling as
a clinically relevant pathway in ERMS,4,5 its functional role in ERMS
pathology and particularly its contribution to the hierarchical
organization seen in ERMS has not been investigated. Here, we
show that hedgehog pathway activity is an important determinant
of ERMS ‘stemness’ features such as self-renewal and tumor
initiation, as previously shown for other malignancies.23 Therefore,
clinical strategies for using hedgehog inhibitors in ERMS would
need to accommodate the conceptual implications of the cancer
stem cell model.24,25 For instance, tumor regression may not be an
appropriate endpoint to estimate treatment efﬁcacy, because the
effect of hedgehog pathway modulation on ERMS pathology was
not due to changes in cell cycle, cell viability or proliferation.
Pathway activation seems to be occurring primarily by autocrine
secretion of IHH and/or DHH. This is in line with an earlier study
ruling out SHH autocrine signaling in ERMS patients.6 Pathway
inhibition was effective at the level of SMO as well as of GLI, which
could avoid emergence of cross talks converging on the GLI-code
and resistance mechanisms in the clinics.9 Furthermore, we found
that modulating the pathway can alter sensitivity to generic drugs.
Therefore, combination therapy with hedgehog inhibitors might
allow the usage of lowered drug doses to reduce treatment-
related morbidity.
Interestingly, our work suggests novel negative feedback
mechanisms between hedgehog signaling and key muscle
differentiation pathways, Wnt, Notch and TGFβ.26–28 Previous
reports show that inhibition of Notch and TGFβ and activation of
Wnt could lead to ERMS differentiation.7,29,30 Interestingly,
activation of the Wnt pathway induced differentiation and
reduced tumor initiation in a RAS-driven zebraﬁsh ERMS model.
The authors also identiﬁed the hedgehog inhibitor cyclopamine as
one of the top drug candidates from a large-scale small molecular
screen that could differentiate ERMS cells and reduce tumor
growth in vivo.31 This study supports our ﬁndings and further
highlights crosstalk between ‘stemness’ pathways that could
deﬁne ERMS TPC behavior. However, the more differentiated
compartments are also likely to have important roles in tumor
progression (this study and Ignatius et al.12).
Previously, PTCH1 mRNA expression in ERMS patients was
shown to predict poor outcome.4 Although PTCH1 mRNA
expression correlates signiﬁcantly with that of GLI1 mRNA (data
not shown and Zibat et al.4), PTCH1 provides negative feedback
cues into the pathway that could obscure the ﬁnal outcome on
cellular self-renewal. Hence, PTCH1 protein expression status may
not be a reliable predictor of prognosis. We reported that ERMS
patients with CD133high expression have poor overall survival,11
but the functional role of CD133 protein is currently unclear. Also,
the impact of other potential ERMS TPCs markers (FGFR3 (ref. 32)
and MYF5 (ref. 12)) on prognosis is unknown. We identify NANOG
as a functionally important gene whose expression along with
GLI1 could serve as novel prognostic indicators. Importantly, we
detected clear GLI1-NANOG co-localization in ERMS PDX cells.
However, we were unable to do so on the TMA tumor cores owing
to the lack of serial sections. Interestingly, we observed hetero-
geneous expression of GLI1 and NANOG also within alveolar RMS
patient tumor cores but without prognostic signiﬁcance (data not
shown). Therefore, the GLI1-NANOG TPC marking could be
important speciﬁcally for ERMS patient stratiﬁcation and further
highlights the biological disparity between the two RMS variants.
Expression of transcription factors important for development
of neural crest-derived mesenchymal and neural tissues, namely
PAX6, PITX2 and LMX1B,33–35 were positively regulated by the
hedgehog pathway, whereas myogenic differentiation factors
were downregulated. Therefore, GLI1-NANOGhigh ERMS cells could
possess a pre-myogenic multipotent phenotype reminiscent of
neural crest or non-myogenic origin for ERMS. This is concordant
with recent observations in hedgehog-activated mouse models,
wherein ERMS ‘cell of origin’ was determined to be from either
pre-somitic or non-muscle mesenchyme.36,37 ERMS cells expres-
sing other potential TPC markers have been described to be
restricted to the skeletal muscle lineage.10,32,38 It is therefore
possible that different ERMS TPC subpopulations with varying
differentiation potentials are concomitantly present within tumors.
The hierarchical relationship between these potential compart-
ments and their relative importance for ERMS tumorigenicity is yet
to be determined and warrants further research.
It is likely that the hedgehog-active TPC phenotype is a
widespread feature because activation of RAS signaling is
common in ERMS1,3 and is known to have a positive inﬂuence
on hedgehog signaling.39 Interestingly, also, the loss of p53 can
increase GLI-NANOG signaling in stem cells and TPCs of neural
origin.20,21 The cell lines used in this study represent these genetic
backgrounds (RD: NRASQ61H; p53R248V and RH36: HRASQ61K). Hence,
hedgehog-driven targeting could be of broad interest in sporadic
ERMS. Our study highlights that phenotypic and functional tumor
heterogeneity could have signiﬁcance for clinical management of
ERMS patients and suggests hedgehog inhibition as a treatment
strategy aimed at reducing the rate of relapse for a long-term cure.
MATERIALS AND METHODS
Patient-derived samples
Early passages of ERMS PDX samples RH70 (SJRHB011_Y), RH72
(SJRHB013_X) and RH73 (SJRHB011_X) were obtained from St. Jude
Children’s Research Hospital (USA) and previously described in detail in.1
All patient tissue specimens used only for RNA extraction were obtained
from the Swiss Pediatric Oncology Group (SPOG) Tumor Bank except
ZH_ERMS, which was obtained from the Department of Pathology,
University Hospital Zurich. The use of SPOG Tumor Bank tissue samples
was approved by the Ethical Review Board of Zurich (Ref. No. StV-18/02).
Written informed consent was obtained from each patient by the hospital
that provided the tissue samples. The TMA used in this study included
multiple tumor cores from 149 RMS patients (116 ERMS and 33 alveolar
RMS) enrolled in the German soft-tissue sarcoma group (CWS) studies -81,
-86, -91 and -96 as previously described.22
Orthotopic xenograft generation
RD (3 × 105cells/mouse) or RH36 (2.5 × 105cells/mouse) were injected into
the femoral muscles of one leg of 4–6-week-old NOD.CB17-Prkdcscid mice
(NOD/SCID; Jackson Laboratory, Bar Harbor, ME, USA). Animals were
chosen from either sex and were assigned randomly to different groups.
Once tumor was palpable, size was determined every 4 days by measuring
two diameters (d1 and d2) in right angles of both legs with a Vernier caliper
until tumors reached the maximum allowed volume of 1000 cm3 or
followed for 120 days. Tumor volumes were calculated using the following
formula: V = [4/3 x π x 1/2(d1+d2)]injected leg [4/3 x π x 1/2(d1+d2)]control leg.
For PDX generation, dissociated cells were resuspended in matrigel
(Corning, Amsterdam, Netherlands) at 1 × 104 cells/μl and 100 μl was
injected as described above.
Freshly isolated xenografts were stored in RNAlater (Ambion, Hunting-
don, Cambridgeshire, UK) for RNA extraction, snap-frozen in liquid N2 for
protein extraction or ﬁxed in 4% paraformaldehyde for imunohistochem-
istry. The experiments were conducted in a non-blind manner and
approved by the veterinary ofﬁce of Canton Zurich.
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Tumor dissociation
PDX samples were minced with scalpels and digested using Liberase DH
(0.62 WU/ml; Roche, Rotkreuz, Switzerland) in buffer containing 1 × HBSS,
10mM HEPES, 200 U/ml DNase (Roche) and 1mM MgCl2, at 37 °C for 70min.
The cells were pelleted, resuspended in Dulbecco's modiﬁed Eagle's media
+10% fetal bovine serum and passed through a cell strainer to remove
debris. Primary cells were plated and maintained in standard culture media
for experiments.
Cell culture and treatments
Human ERMS cell lines RD (ATCC, Manassas, VA, USA), RH36, RH18 (both
kindly provided by Peter Houghton, St. Jude’s Children’s Hospital, USA) and
TTC442 (kindly provided by Timothy J. Triche, Children’s Hospital Los
Angeles, USA) were cultured in Dulbecco's modiﬁed Eagle's media
supplemented with 10% fetal bovine serum, 2mM L-glutamine and
100 U/ml penicillin-streptomycin. Sphere cultures were maintained as
previously described.11 The cell lines were authenticated by short tandem
repeat analysis and regularly checked for mycoplasma contamination. For
sphere formation, equal numbers of cells were plated at clonal density in
Ultra-Low attachment plates (Corning). Primary spheres were dissociated
using Accutase (Sigma-Aldrich, Buchs, Switzerland) and stained with
Trypan Blue solution (Sigma-Aldrich) for counting. Equal numbers of viable
sphere cells were plated for secondary sphere formation. For single cell
cloning, RD cells were plated in 96-well plates in stringent single cell
dilution (0.5 cell/well) in normal adherent culture media. After 16 h, the
wells with single cells were marked and followed for viable colony
formation. Upon reaching conﬂuency, the cultures were propagated in
larger plate formats. Drugs used included SMO inhibitors GDC-0449 and
LDE-225 (Selleck, Munich, Germany), GLI inhibitor GANT61 (Tocris, Bristol,
UK) and GLI activator SAG1.3 (Calbiochem, San Diego, CA, USA). For IC50
measurements of irinotecan (SN-38; Sigma-Aldrich) and doxorubicin
(Sandoz, Rotkreuz, Switzerland), cells were plated in quadruplicate in
96-well plates and treated with ﬁve-step serial dilutions for 72 h in 10%
fetal bovine serum media. Dimethyl sulfoxide (Sigma-Aldrich) was used as
vehicle control except for SAG1.3 (diluted in water).
siRNA transfection
Adherent cells were transfected with Silencer select siRNAs (Ambion, Life
technologies) against GLI1 (#1: s5814; #2: s5816), SUFU (#1: s28520; #2:
s28521), NANOG (#1: s36649; #2: s36650) or scrambled control (Silencer
Negative Control# 2) using Lipofectamine RNAiMAX (Invitrogen, Zug,
Switzerland) at a ﬁnal concentration of 10 nM. Sphere growth was initiated
24 h post transfection.
Cell viability, proliferation and clonogenic assays
To assess cell viability and proliferation, cells were plated in quadruplicate
per condition in 96-well plates. After treatment, viability was measured
using WST-1 (Roche). Cell proliferation was measured 24 h post plating
using Cell Proliferation ELISA, BrdU (chemiluminescent) assay (Roche).
Clonogenic assay was performed as described by Franken et al.40 In brief,
cells were seeded in dilution of 1 cell/μl in six-well plates in normal culture
media. Media was changed every 3 days until colonies (450 cells) were
visible. Cells were ﬁxed and stained using with Crystal Violet staining
solution (0.5% Crystal Violet and 6% gluteraldehye in water). Colonies were
quantiﬁed using ImageJ software (version 1.47).
Quantitative PCR
Normal human skeletal muscle pooled RNA lysate, referred to as AdSkM_P,
from ﬁve adults (R1234171_P) and individual RNA lysates from three fetal
donors (R1244171; Lot # A503105, B505186, A508111) were purchased
from (Amsbio, Lugano, Switzerland). Total RNA was extracted using RNeasy
Mini Kit (Qiagen, Basel, Switzerland) with RNase-free DNase. Normal murine
muscle RNA was extracted from femoral muscle of NOD/SCID mice.
Complementary DNA synthesis was carried out using High-Capacity cDNA
Reverse Transcription kit (Life Technologies, Zug, Switzerland). QPCR was
performed using Taqman mastermix and Gene Expression Assays
(Life Technologies; assay IDs are listed in Supplementary Table 1). Absolute
and relative expression levels were calculated using the ΔΔCt method and
normalized to HMBS (unless otherwise speciﬁed) or GAPDH. For screening,
RT2 Proﬁler PCR Arrays (Stem Cell Signaling (PAHS-047ZE) and Stem Cell
Transcription Factors (PAHS-501ZE)) were purchased from Qiagen. Data
analysis was performed using the RT2 Proﬁler PCR Array Analysis
web-based software (version 3.5). Non-supervised hierarchical clustering
was performed using by dChip.
Western blotting and immunoﬂuorescence
Total protein was extracted using RIPA buffer (50mM Tris-Cl, pH 6.8,
100mM NaCl, 1% Triton X-100, 0.1% SDS) supplemented with Complete
Mini Protease Inhibitor Cocktail (Roche). Proteins were separated using
NuPAGE gradient SDS–PAGE pre-cast gels (Life Technologies) and detected
by chemiluminescence using Amersham ECL Detection reagent
(GE Healthcare, Glattbrugg, Switzerland) or SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Scientiﬁc, St Leon-Rot, Germany).
For immunoﬂuorescence, cells were ﬁxed with 4% paraformaldehyde and
incubated over night at 4 °C with primary antibodies. All the antibodies
and further details are listed in Supplementary Table 2.
TMA scoring and data analysis
TMA was evaluated by a senior pathologist (PB). A minimum of two
desmin-positive intact cores was required for the patient to be included in
the analysis. At least three stained cells were required to label a patient as
positive. Tumors from 91 ERMS and 23 alveolar RMS patients provided
reliable GLI1 and NANOG expression status. Clinical data were analyzed
independently by CWS study member (SF) who was blind to the
hypothesis. Statistical analysis was performed using SPSS software (version
21, (IBM, Armonk, NY, USA)) based on all data available up to the cutoff
date, 05.04.2013. Differences in survival rates were analyzed using the log-
rank test.
Statistical analysis
Data were analyzed using GraphPad Prism (version 4.03). Signiﬁcance was
calculated using Student’s t-test (unpaired, two-tailed), and if the variance
was found to be signiﬁcantly different by F-test, then Welch’s correction
was used. Normal distribution of data was assessed using D’Agostino and
Pearson normality test. Mann–Whitney test was used to assess signiﬁcance
when data were non-parametric. Tumor growth curves were compared
using two-way analysis of variance with Bonferroni post hoc tests. Only
animals that showed tumor growth were included in the ﬁnal analysis.
Po0.05 was considered signiﬁcant. The total sample size (‘n’) and
biological replicates (‘N’) per condition per experiment are indicated in
the ﬁgure legends. Each experiment was replicated at least twice. Data are
represented as mean with s.d. as error bars unless otherwise mentioned.
No power analysis was used to pre-determine sample size.
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